And now,

kidneyintelX.dkd: what it is vs. what it’s not

IS IS NOT
Focused, almost exclusively, on assisting nephrologists with their chronic kidney disease patients in stages 4 and 5 who are transitioning to dialysis or transplant.
Recognized as the first and only FDA authorized prognostic test for assessment of risk of chronic kidney disease progression. It sets the bar as a predicate for same or like medical tests to be reviewed by the FDA in the future.
Provides primary care doctors with a test to assess risk of progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. This allows PCPs to identify risk earlier to improve kidney outcomes and overall patient health.
Our test reliably assesses where each adult patient with type 2 diabetes and with chronic kidney disease stages 1-3b falls on the risk spectrum for kidney disease progression (High/Moderate/Low).
Only test that leverages the three proprietary biomarkers demonstrated to be highly prognostic for chronic kidney disease progression.
Supported by a clinical validation study,  kidneyintelX.dkd demonstrated an unadjusted HR for high vs low risk at 18-fold and 8-fold, respectively, when adjusted for age, sex, race, eGFR, UACR, A1C and BP.
The only test for progressive decline in kidney function with a national payment rate and final coverage determination from Medicare.
Is:

Recognized as the first and only FDA authorized prognostic test for assessment of risk of chronic kidney disease progression. It sets the bar as a predicate for same or like medical tests to be reviewed by the FDA in the future.

Provides primary care doctors with a test to assess risk of progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease stages 1-3. This allows PCPs to identify risk earlier to improve kidney outcomes and overall patient health.

Our test reliably assesses where each adult patient with type 2 diabetes and with chronic kidney disease stages 1-3 falls on the risk spectrum for kidney disease progression (High/Moderate/Low).

Only test that leverages the three proprietary biomarkers demonstrated to be highly prognostic for chronic kidney disease progression.

Supported by a clinical validation study, kidneyintelX.dkd demonstrated an unadjusted HR for high vs low risk at 18-fold and 8-fold, respectively, when adjusted for age, sex, race, eGFR, UACR, A1C and BP.

The only test for progressive decline in kidney function with a national payment rate and final coverage determination from Medicare.

Is not:

Focused, almost exclusively, on assisting nephrologists with their chronic kidney disease patients in stages 4 and 5 who are transitioning to dialysis or transplant.